Shenzhen Mindray Bio-Medical Electronics (300760) Earnings: 1H Revenue Aligns with Estimates at 20.53 Billion Yuan

Shenzhen Mindray Bio-Medical Electronics on Smartkarma

Analyst coverage of Shenzhen Mindray Bio-Medical Electronics on Smartkarma by Xinyao (Criss) Wang suggests a cautious outlook. In the report titled “Time to Bring ‘New Growth Story’ To Investors,” the analyst highlights concerns about the company’s sluggish growth and forecasts a further decrease in YoY revenue growth to 15%. Without new growth drivers, maintaining a high valuation may become challenging for Mindray. The report casts doubt on the potential growth from the recovery of routine diagnosis and treatment post-COVID-19 for Mindray’s MI/IVD businesses. Wang warns that without significant changes, achieving over 20% revenue growth in 2024 could be difficult. The analyst suggests a PE ratio range of 25-30 as reasonable, advising a long position if the PE falls to 20-25.

A look at Shenzhen Mindray Bio-Medical Electronics Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Shenzhen Mindray Bio-Medical Electronics is positioned for strong long-term performance based on its Smartkarma Smart Scores. With a solid rating for both dividend and momentum, investors can expect stable returns and a company that is gaining traction in the market. The high growth and resilience scores further indicate a promising future for the company, showcasing its ability to innovate and adapt to changing market conditions.

As a manufacturer and distributor of medical equipment, Shenzhen Mindray Bio-Medical Electronics focuses on life information supporting, in vitro diagnostic, and medical imaging equipment. Additionally, the company produces supporting reagents, enhancing its portfolio of offerings in the healthcare sector. With favorable Smart Scores across key factors, Shenzhen Mindray Bio-Medical Electronics appears well-positioned to deliver value and growth to investors in the coming years.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma